CN114929865A - 作为过继细胞疗法的基因工程化双阴性t细胞 - Google Patents

作为过继细胞疗法的基因工程化双阴性t细胞 Download PDF

Info

Publication number
CN114929865A
CN114929865A CN202080091459.0A CN202080091459A CN114929865A CN 114929865 A CN114929865 A CN 114929865A CN 202080091459 A CN202080091459 A CN 202080091459A CN 114929865 A CN114929865 A CN 114929865A
Authority
CN
China
Prior art keywords
dnt
cells
genetically modified
cell
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080091459.0A
Other languages
English (en)
Chinese (zh)
Inventor
张丽
J·B·李
D·瓦西奇
I·卡特里
D·莱
Y·S·L·梁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN114929865A publication Critical patent/CN114929865A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080091459.0A 2019-12-06 2020-12-07 作为过继细胞疗法的基因工程化双阴性t细胞 Pending CN114929865A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944634P 2019-12-06 2019-12-06
US62/944,634 2019-12-06
PCT/CA2020/051682 WO2021108926A1 (en) 2019-12-06 2020-12-07 Genetically engineered double negative t cells as an adoptive cellular therapy

Publications (1)

Publication Number Publication Date
CN114929865A true CN114929865A (zh) 2022-08-19

Family

ID=76221295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091459.0A Pending CN114929865A (zh) 2019-12-06 2020-12-07 作为过继细胞疗法的基因工程化双阴性t细胞

Country Status (6)

Country Link
US (1) US20230011889A1 (https=)
EP (1) EP4069831A4 (https=)
JP (1) JP2023505192A (https=)
CN (1) CN114929865A (https=)
CA (1) CA3160422A1 (https=)
WO (1) WO2021108926A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113528449A (zh) * 2020-04-20 2021-10-22 浙江瑞加美生物科技有限公司 一种制备通用型人源化car19-dnt细胞的技术及其应用
EP4458378A4 (en) * 2021-12-30 2025-07-09 Chongqing Prec Biotech Co Ltd TECHNIQUE FOR PREPARING A UNIVERSAL CAR-T CELL, AND APPLICATION OF A UNIVERSAL CAR-T CELL
WO2025106552A1 (en) * 2023-11-14 2025-05-22 Nkarta, Inc. Methods and compositions for treatment of leukemia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097140A1 (en) * 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
CN104789595A (zh) * 2015-04-20 2015-07-22 范国煌 嵌合抗原受体双阴性t细胞的构建方法
US20170049818A1 (en) * 2008-01-30 2017-02-23 Memorial Sloan-Kettering Cancer Center Methods for off-the-shelf-tumor immunotherapy using allogeneic t-cell precursors
CN107828730A (zh) * 2017-11-07 2018-03-23 南京北恒生物科技有限公司 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097140A1 (en) * 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
US20170049818A1 (en) * 2008-01-30 2017-02-23 Memorial Sloan-Kettering Cancer Center Methods for off-the-shelf-tumor immunotherapy using allogeneic t-cell precursors
CN104789595A (zh) * 2015-04-20 2015-07-22 范国煌 嵌合抗原受体双阴性t细胞的构建方法
CN107828730A (zh) * 2017-11-07 2018-03-23 南京北恒生物科技有限公司 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEE J等: "Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms", 《CLIN CANCER RES》, vol. 24, no. 2, 26 October 2017 (2017-10-26), pages 370 - 382 *
VASIC D等: "Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities", 《IMMUNOL》, vol. 7, no. 70, 22 April 2022 (2022-04-22), pages 1 - 15 *
YAO J等: "Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15", 《 J IMMUNOTHER CANCER》, vol. 7, no. 1, 22 January 2019 (2019-01-22), pages 1 - 14 *
赵富国主编: "《医学免疫学》", 30 April 2013, 人民军医出版社, pages: 104 *

Also Published As

Publication number Publication date
CA3160422A1 (en) 2021-06-10
WO2021108926A1 (en) 2021-06-10
US20230011889A1 (en) 2023-01-12
EP4069831A1 (en) 2022-10-12
JP2023505192A (ja) 2023-02-08
EP4069831A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
Maury et al. CD4+ CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation
Guo et al. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells
CN114786687A (zh) 用于过继细胞疗法的Cbl抑制剂和组合物
Suck et al. Natural killer cells for therapy of leukemia
CN113766919B (zh) 制造抗bcma car t细胞
CN115137752A (zh) 用于干细胞移植的方法
CN114929865A (zh) 作为过继细胞疗法的基因工程化双阴性t细胞
Anam et al. Amnion-derived multipotent progenitor cells support allograft tolerance induction
EP3940063A2 (en) Method for the expansion and differentiation of t lymphocytes and nk cells in adoptive transfer therapies
Bouchlaka et al. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects
KR20250006881A (ko) 혈액암의 치료를 위한 동종 t 세포
CN113454209A (zh) 通用型双阴性t细胞的制备和治疗用途
Wang et al. CD122+ CD8+ Treg suppress vaccine‐induced antitumor immune responses in lymphodepleted mice
Bryson et al. Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease
CN107073039A (zh) 用于癌症治疗的免疫疗法
West et al. Pluripotent allospecific CD8+ effector T cells traffic to lung in murine obliterative airway disease
Ghosh et al. Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors
Fousteri et al. Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure
WO2025055493A1 (zh) 基因编辑的肿瘤浸润淋巴细胞及其在免疫细胞治疗中的应用
Luo et al. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies
HK40079239A (en) Genetically engineered double negative t cells as an adoptive cellular therapy
Al Malki et al. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium—Haplo2014, San Francisco, California, December 4, 2014
JP2024536217A (ja) 操作されたｎｋ細胞及びその使用
Perico et al. A modern view of transplant immunology and immunosuppression
MacDonald et al. Donor pretreatment with progenipoietin-1 is superior to G-CSF in preventing graft-versus-host disease after allogeneic stem cell transplantation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079239

Country of ref document: HK